Segment and Geographical Data (Schedule of Segment Reporting Information by Business Segment) (Details) (USD $)	3 Months Ended											12 Months Ended
	Sep. 26, 2014		Jun. 27, 2014	Mar. 28, 2014	Dec. 27, 2013	Sep. 27, 2013		Jun. 28, 2013		Mar. 29, 2013	Dec. 28, 2012	Sep. 26, 2014		Sep. 27, 2013		Sep. 28, 2012
Segment Reporting Information [Line Items]
Net sales	$ 789,300,000		$ 653,100,000	$ 557,800,000	$ 540,200,000	$ 545,200,000		$ 570,000,000	[1]	$ 585,300,000	$ 504,000,000	$ 2,540,400,000		$ 2,204,500,000		$ 2,056,200,000
Operating income (loss)												(284,100,000)		144,800,000		235,200,000
Intangible asset amortization												(162,300,000)		(35,400,000)		(27,300,000)
Restructuring and related charges, net												(129,100,000)		(35,800,000)		(19,200,000)
Non-restructuring impairment												355,600,000		0		0
Separation costs												(9,600,000)		(74,200,000)		(25,500,000)
Assets	12,864,800,000					3,556,600,000						12,864,800,000		3,556,600,000
Depreciation and amortization												275,900,000		139,600,000		130,900,000
Restructuring and related costs, accelerated depreciation												500,000		2,600,000		8,000,000
Specialty Pharmaceuticals
Segment Reporting Information [Line Items]
Restructuring and related charges, net												(66,800,000)		(16,400,000)		(11,300,000)
Global Medical Imaging
Segment Reporting Information [Line Items]
Restructuring and related charges, net												(60,900,000)		(16,400,000)		(7,900,000)
Operating Segments
Segment Reporting Information [Line Items]
Net sales												2,494,400,000	[2]	2,153,300,000	[2]	2,002,000,000	[2]
Operating income (loss)												613,900,000		424,000,000		377,100,000
Operating Segments | Specialty Pharmaceuticals
Segment Reporting Information [Line Items]
Net sales												1,612,900,000		1,217,600,000		1,005,200,000
Operating income (loss)												566,800,000		311,700,000		162,800,000
Assets	10,913,700,000					1,666,600,000						10,913,700,000		1,666,600,000
Depreciation and amortization												230,700,000	[3]	97,600,000	[3]	88,700,000	[3]
Operating Segments | Global Medical Imaging
Segment Reporting Information [Line Items]
Net sales												881,500,000		935,700,000		996,800,000
Operating income (loss)												47,100,000		112,300,000		214,300,000
Assets	663,300,000					1,158,600,000						663,300,000		1,158,600,000
Depreciation and amortization												45,200,000	[3]	42,000,000	[3]	42,200,000	[3]
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Net sales												46,000,000	[4]	51,200,000	[4]	54,200,000	[4]
Corporate and allocated expenses												(241,400,000)	[5]	(133,800,000)	[5]	(69,900,000)	[5]
Intangible asset amortization												(162,300,000)		(35,400,000)		(27,300,000)
Restructuring and related charges, net												(129,100,000)	[6]	(35,800,000)	[6]	(19,200,000)	[6]
Non-restructuring impairment												(355,600,000)		0		0
Separation costs												(9,600,000)		(74,200,000)		(25,500,000)
Assets	1,287,800,000	[7]				731,400,000	[7]					1,287,800,000	[7]	731,400,000	[7]
Intersegment Eliminations
Segment Reporting Information [Line Items]
Net sales												$ 0		$ 0		$ 0

[1] Operations in the third quarter of fiscal 2013 were impacted by the Separation.

[2] Amounts represent sales to external customers. There were no intersegment sales.

[3] Depreciation for certain shared facilities is allocated based on occupancy percentage.

[4] Represents products that were sold to Covidien, which is discussed in Note 16.

[5] Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.

[6] Includes restructuring-related accelerated depreciation of $0.5 million, $2.6 million and $8.0 million for fiscal 2014, 2013 and 2012, respectively.

[7] Consists of assets used in managing the Company's total business and not allocated to any one segment.